267 related articles for article (PubMed ID: 9433371)
1. Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells.
Yanni JM; Miller ST; Gamache DA; Spellman JM; Xu S; Sharif NA
Ann Allergy Asthma Immunol; 1997 Dec; 79(6):541-5. PubMed ID: 9433371
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases.
Sharif NA; Xu SX; Miller ST; Gamache DA; Yanni JM
J Pharmacol Exp Ther; 1996 Sep; 278(3):1252-61. PubMed ID: 8819509
[TBL] [Abstract][Full Text] [Related]
3. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent.
Yanni JM; Stephens DJ; Miller ST; Weimer LK; Graff G; Parnell D; Lang LS; Spellman JM; Brady MT; Gamache DA
J Ocul Pharmacol Ther; 1996; 12(4):389-400. PubMed ID: 8951675
[TBL] [Abstract][Full Text] [Related]
4. Ocular anti-allergic compounds selectively inhibit human mast cell cytokines in vitro and conjunctival cell infiltration in vivo.
Galatowicz G; Ajayi Y; Stern ME; Calder VL
Clin Exp Allergy; 2007 Nov; 37(11):1648-56. PubMed ID: 17877767
[TBL] [Abstract][Full Text] [Related]
5. Olopatadine inhibits TNFalpha release from human conjunctival mast cells.
Cook EB; Stahl JL; Barney NP; Graziano FM
Ann Allergy Asthma Immunol; 2000 May; 84(5):504-8. PubMed ID: 10831003
[TBL] [Abstract][Full Text] [Related]
6. Olopatadine inhibits anti-immunoglobulin E-stimulated conjunctival mast cell upregulation of ICAM-1 expression on conjunctival epithelial cells.
Cook EB; Stahl JL; Barney NP; Graziano FM
Ann Allergy Asthma Immunol; 2001 Nov; 87(5):424-9. PubMed ID: 11730187
[TBL] [Abstract][Full Text] [Related]
7. Olopatadine: a drug for allergic conjunctivitis targeting the mast cell.
Leonardi A; Quintieri L
Expert Opin Pharmacother; 2010 Apr; 11(6):969-81. PubMed ID: 20307221
[TBL] [Abstract][Full Text] [Related]
8. Interactions of olopatadine and selected antihistamines with model and natural membranes.
Brockman HL; Momsen MM; Knudtson JR; Miller ST; Graff G; Yanni JM
Ocul Immunol Inflamm; 2003 Dec; 11(4):247-68. PubMed ID: 14704897
[TBL] [Abstract][Full Text] [Related]
9. Mast cell stabilization and anti-histamine effects of olopatadine ophthalmic solution: a review of pre-clinical and clinical research.
Rosenwasser LJ; O'Brien T; Weyne J
Curr Med Res Opin; 2005 Sep; 21(9):1377-87. PubMed ID: 16197656
[TBL] [Abstract][Full Text] [Related]
10. A current appreciation of sites for pharmacological intervention in allergic conjunctivitis: effects of new topical ocular drugs.
Yanni JM; Sharif NA; Gamache DA; Miller ST; Weimer LK; Spellman JM
Acta Ophthalmol Scand Suppl; 1999; (228):33-7. PubMed ID: 10337430
[TBL] [Abstract][Full Text] [Related]
11. Bepotastine besilate, a highly selective histamine H(1) receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models.
Kida T; Fujii A; Sakai O; Iemura M; Atsumi I; Wada T; Sakaki H
Exp Eye Res; 2010 Jul; 91(1):85-91. PubMed ID: 20412793
[TBL] [Abstract][Full Text] [Related]
12. [Toxicity of topical ocular anti-allergic agents on human corneal epithelial cells in vitro].
Li J; Yan XM
Zhonghua Yan Ke Za Zhi; 2010 Jan; 46(1):43-50. PubMed ID: 20388322
[TBL] [Abstract][Full Text] [Related]
13. Olopatadine (AL-4943A): ligand binding and functional studies on a novel, long acting H1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis.
Sharif NA; Xu SX; Yanni JM
J Ocul Pharmacol Ther; 1996; 12(4):401-7. PubMed ID: 8951676
[TBL] [Abstract][Full Text] [Related]
14. Characterization of primate bronchoalveolar mast cells. II. Inhibition of histamine, LTC4, and PGD2 release from primate bronchoalveolar mast cells and a comparison with rat peritoneal mast cells.
Wells E; Jackson CG; Harper ST; Mann J; Eady RP
J Immunol; 1986 Dec; 137(12):3941-5. PubMed ID: 2431049
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial.
Avunduk AM; Tekelioglu Y; Turk A; Akyol N
Clin Ther; 2005 Sep; 27(9):1392-402. PubMed ID: 16291412
[TBL] [Abstract][Full Text] [Related]
16. Azelastine's inhibition of histamine and tryptase release from human umbilical cord blood-derived cultured mast cells as well as rat skin mast cell-induced vascular permeability: comparison with olopatadine.
Lytinas M; Kempuraj D; Huang M; Kandere K; Boucher W; Letourneau R; Jeudy S; Fitzgerald K; Spear K; Athanasiou A; Theoharides TC
Allergy Asthma Proc; 2002; 23(1):45-51. PubMed ID: 11894734
[TBL] [Abstract][Full Text] [Related]
17. Nedocromil sodium and levocabastine reduce the symptoms of conjunctival allergen challenge by different mechanisms.
Ahluwalia P; Anderson DF; Wilson SJ; McGill JI; Church MK
J Allergy Clin Immunol; 2001 Sep; 108(3):449-54. PubMed ID: 11544467
[TBL] [Abstract][Full Text] [Related]
18. Azelastine is more potent than olopatadine n inhibiting interleukin-6 and tryptase release from human umbilical cord blood-derived cultured mast cells.
Kempuraj D; Huang M; Kandere K; Boucher W; Letourneau R; Jeudy S; Fitzgerald K; Spear K; Athanasiou A; Theoharides TC
Ann Allergy Asthma Immunol; 2002 May; 88(5):501-6. PubMed ID: 12027072
[TBL] [Abstract][Full Text] [Related]
19. Anti-allergic cromones inhibit histamine and eicosanoid release from activated human and murine mast cells by releasing Annexin A1.
Yazid S; Sinniah A; Solito E; Calder V; Flower RJ
PLoS One; 2013; 8(3):e58963. PubMed ID: 23527056
[TBL] [Abstract][Full Text] [Related]
20. Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans.
Leonardi A; Abelson MB
Clin Ther; 2003 Oct; 25(10):2539-52. PubMed ID: 14667955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
